MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Organization & Developments: Royalty Pharma
Parents
Royalty Pharma plc (NASDAQ:RPRX)
Children
*Collaborates with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
*Industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products.
*Portfolio products include Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Gilead's Emtriva®, Truvada® and Atripla®, Celgene's Thalomid®, Abbott's Humira®, J&J's Remicade®, Pfizer's Lyrica®, Gilead's Letairis®, GlaxoSmithKline's Volibris® and Genzym
*Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products with a market value of over $6 billion.
2011: Royalty Pharma Acquires Lexiscan(R) and Cubicin(R) Royalties for $487 Million
2017: The Private Equity Firm That Quietly Profits on Top-Selling Drugs
2020: Royalty Pharma Acquires Additional Royalty Interest from the Cystic Fibrosis Foundation – Royalty Pharma
2020: Royalty Pharma purchased all of the CF Foundation’s royalty interests on Vertex’s CF franchise.
2020: Royalty Pharma: Business Model May Be Oversold, But Shares Are Undervalued And Could Trade >$80
2021: Royalty Pharma Provides Unique Diversity To A Biopharma Portfolio
2021: Royalty Pharma: A Potentially Long-Term Dividend Investment
2021: Royalty Pharma: Generating Yield In The Biotech Realm
2022: Royalty Pharma plc 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Royalty Pharma: Unique Diversification, Bear Market Performer_seekingalpha.com
2024: Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
2024: Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
2024: Royalty Pharma plc 2023 Q4 - Results - Earnings Call Presentation
2024: Royalty Pharma: Massive Opportunity Ahead
2024: Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
2025: Is Geron A Buyout Target? The RPRX Deal Says No
2025: Royalty Pharma Announces R&D Funding Collaboration With Biogen
2025: Royalty Pharma raises quarterly dividend by 5% to $0.22/share_ seekingalpha.com
2025: Royalty pharma to buy its external manager, announces $3B share buyback
2025: Royalty Pharma: Delivering Growth With A Positive Story Ahead
2025: Royalty Pharma: Key Strategic Updates To Be Priced In
2026: RPRX Financials: Income Statement, Balance Sheet & Cash Flow
Jumps
*Key People: Royalty Pharma
Finance & Acquisitions: Royalty Pharma